Long-term Safety and Efficacy of Prebiotic Enriched Infant Formula
Primary Purpose
Infection, Microbial Colonization, Healthy
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Supplemented formula
Standard formula
Sponsored by

About this trial
This is an interventional basic science trial for Infection
Eligibility Criteria
Inclusion Criteria:
- Healthy babies born between 37 - 42 weeks of gestation and with weight appropriate for gestational age (between percentiles 3 and 97)
- Healthy babies aged between 0 - 4 months of age
- Babies exclusively fed with an infant formula on enrolment into the study
Exclusion Criteria:
- The presence of an infection at the moment of the recruitment or 1 week before recruitment
- The presence of important pathologies (intestinal, cardiopathy, mental retardation, etc.)
- Any other diseases related to the immune system (primary immunodeficiency)
- Parents not able to comply with the study follow up (according to physician criteria)
Sites / Locations
- ZNA Koningin Paola Kinderziekenhuis
- Universitair Ziekenhuis
- CAP Llefià
- Hospital de Nens
- Hospital Sant Joan de Deu
- University Hospital Vall d'Hebron
- Hospital San Cecilio
- Equipo Pediátrico San Francisco
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
supplemented formula
standard formula
Arm Description
Standard formula supplemented with prebiotic inulin-type fructans
Standard Formula not supplemented with prebiotic inulin-type fructans
Outcomes
Primary Outcome Measures
Incidence of infections during first year of life
measured through presence of fever, and number and duration of infectious episodes
Secondary Outcome Measures
Stool frequency
Number of depositions per day assessed by parenteral reporting (parent's diary collected during first week of each study month throughout all study period)
Stool consistency
Assessed via 1-3 scale with pictograms (1=hard, 2=soft/formed, 3=liquid/semi-liquid), by parenteral reporting (parent's diary collected during first week of each study month throughout all study period)
Digestive tolerance
Number of vomiting and regurgitation episodes per day and presence of excessive flatulence and infantile colic, assessed by parenteral reporting (parent's diary collected during first week of each study month throughout all study period)
Growth
Calculation of z-scores of weight-for-age and length-for-age according to the World Health Organisation (WHO) standards using WHO software (WHO Antro software).
Body weight
Assessment of weight (kg) of the nude infant via calibrated electronic scales at all study visits.
Body height
Assessment of height (cm) in supine position by using a standard measuring board at all study visits.
Head circumference
Assessment of head circumference (cm) using a non-extendable insertion tape at all study visits.
Sleeping habits
Assessment of total hours slept and total hours of nocturnal sleeping per day (min), by parenteral reporting (parent's diary collected during first week of each study month throughout all study period).
Crying episodes
Assessment of crying episodes (min), by parenteral reporting (parent's diary collected during first week of each study month throughout all study period).
Effect on fecal microbiota composition
Quantification of dominant bacterial groups
Effect on development of allergy
Presence of clinical symptoms compatible with food allergies, atopic dermatitis, exanthema
Effect on immunology markers in feces
secretory immunoglobulin A, calprotectin level
Full Information
NCT ID
NCT04441359
First Posted
June 10, 2020
Last Updated
June 18, 2020
Sponsor
Beneo-Institute
Collaborators
Laboratorios Ordesa, European Union
1. Study Identification
Unique Protocol Identification Number
NCT04441359
Brief Title
Long-term Safety and Efficacy of Prebiotic Enriched Infant Formula
Official Title
Effects of the Supplementation With Oligosaccharides on the Prevention of Infections in Infants
Study Type
Interventional
2. Study Status
Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
June 1, 2008 (Actual)
Primary Completion Date
October 31, 2010 (Actual)
Study Completion Date
October 31, 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beneo-Institute
Collaborators
Laboratorios Ordesa, European Union
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of the present study was to evaluate the effects of long-term supplementation of an infant formula supplemented with prebiotic inulin-type oligosaccharides on immunological-health related outcomes.
Detailed Description
The study primarily aimed to evaluate the effects of long-term supplementation of an infant formula with a mixture of short and long chain inulin-type oligosaccharides on immunological-health related outcomes, as well as on gastrointestinal function and well-being in infants during the first year of life. Effects on infant growth, tolerance and on the composition of fecal microbiota were further objectives of this study. The study was conducted as a multicenter, randomised, double-blind, placebo-controlled study in healthy term infants. The two groups of the study are product group (standard infant formula supplemented with inulin-type fructans) and control group (non-supplemented standard infant formula).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection, Microbial Colonization, Healthy
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Actual)
8. Arms, Groups, and Interventions
Arm Title
supplemented formula
Arm Type
Experimental
Arm Description
Standard formula supplemented with prebiotic inulin-type fructans
Arm Title
standard formula
Arm Type
Placebo Comparator
Arm Description
Standard Formula not supplemented with prebiotic inulin-type fructans
Intervention Type
Other
Intervention Name(s)
Supplemented formula
Intervention Description
standard infant formula supplemented with 8 g/L prebiotic inulin-type fructans
Intervention Type
Other
Intervention Name(s)
Standard formula
Intervention Description
standard infant formula not supplemented with prebiotic inulin-type fructans
Primary Outcome Measure Information:
Title
Incidence of infections during first year of life
Description
measured through presence of fever, and number and duration of infectious episodes
Time Frame
until infant reaches age of 1 year
Secondary Outcome Measure Information:
Title
Stool frequency
Description
Number of depositions per day assessed by parenteral reporting (parent's diary collected during first week of each study month throughout all study period)
Time Frame
until infant reaches age of 1 year
Title
Stool consistency
Description
Assessed via 1-3 scale with pictograms (1=hard, 2=soft/formed, 3=liquid/semi-liquid), by parenteral reporting (parent's diary collected during first week of each study month throughout all study period)
Time Frame
until infant reaches age of 1 year
Title
Digestive tolerance
Description
Number of vomiting and regurgitation episodes per day and presence of excessive flatulence and infantile colic, assessed by parenteral reporting (parent's diary collected during first week of each study month throughout all study period)
Time Frame
until infant reaches age of 1 year
Title
Growth
Description
Calculation of z-scores of weight-for-age and length-for-age according to the World Health Organisation (WHO) standards using WHO software (WHO Antro software).
Time Frame
until infant reaches age of 1 year
Title
Body weight
Description
Assessment of weight (kg) of the nude infant via calibrated electronic scales at all study visits.
Time Frame
until infant reaches age of 1 year
Title
Body height
Description
Assessment of height (cm) in supine position by using a standard measuring board at all study visits.
Time Frame
until infant reaches age of 1 year
Title
Head circumference
Description
Assessment of head circumference (cm) using a non-extendable insertion tape at all study visits.
Time Frame
until infant reaches age of 1 year
Title
Sleeping habits
Description
Assessment of total hours slept and total hours of nocturnal sleeping per day (min), by parenteral reporting (parent's diary collected during first week of each study month throughout all study period).
Time Frame
until infant reaches age of 1 year
Title
Crying episodes
Description
Assessment of crying episodes (min), by parenteral reporting (parent's diary collected during first week of each study month throughout all study period).
Time Frame
until infant reaches age of 1 year
Title
Effect on fecal microbiota composition
Description
Quantification of dominant bacterial groups
Time Frame
until infant reaches age of 1 year
Title
Effect on development of allergy
Description
Presence of clinical symptoms compatible with food allergies, atopic dermatitis, exanthema
Time Frame
until infant reaches age of 1 year
Title
Effect on immunology markers in feces
Description
secretory immunoglobulin A, calprotectin level
Time Frame
until infant reaches age of 1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
4 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy babies born between 37 - 42 weeks of gestation and with weight appropriate for gestational age (between percentiles 3 and 97)
Healthy babies aged between 0 - 4 months of age
Babies exclusively fed with an infant formula on enrolment into the study
Exclusion Criteria:
The presence of an infection at the moment of the recruitment or 1 week before recruitment
The presence of important pathologies (intestinal, cardiopathy, mental retardation, etc.)
Any other diseases related to the immune system (primary immunodeficiency)
Parents not able to comply with the study follow up (according to physician criteria)
Facility Information:
Facility Name
ZNA Koningin Paola Kinderziekenhuis
City
Antwerp
Country
Belgium
Facility Name
Universitair Ziekenhuis
City
Brussel
Country
Belgium
Facility Name
CAP Llefià
City
Barcelona
Country
Spain
Facility Name
Hospital de Nens
City
Barcelona
Country
Spain
Facility Name
Hospital Sant Joan de Deu
City
Barcelona
Country
Spain
Facility Name
University Hospital Vall d'Hebron
City
Barcelona
Country
Spain
Facility Name
Hospital San Cecilio
City
Granada
Country
Spain
Facility Name
Equipo Pediátrico San Francisco
City
Madrid
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
Citation
Rodriguez-Palmero, M.; Campoy, C.; Urraca, O.; Alonso, J.; Maldonado, J.; Varea, V.; Palencia, J.; Veereman-Wauters, G.; Neumer, F.; Rivero, M.; Vandenplas, Y. Effects of long-term supplementation with a mixture of short and long chain inulin-type oligosaccharides (2013), Annals of Nutrition and Metabolism, suppl. 1, (63), 1-1960.
Results Reference
result
Learn more about this trial
Long-term Safety and Efficacy of Prebiotic Enriched Infant Formula
We'll reach out to this number within 24 hrs